Search
Close this search box.

About Us

Company/History

Proven Performance, Sensational Results

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive, and cost-effective treatments for both oncological and non-oncological conditions.

Sensus offers its proprietary low-energy photon radiotherapy known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

The People Behind Sensus

Joseph C. Sardano​
Co-Founder, Chairman & CEO​
Michael Sardano​
President & General Counsel​
Javier Rampolla
Chief Financial Officer​
Maggie Martinez​
Chief Operational Officer
Emiliano Sosa​
Chief Technology Officer​
Monica DiGioia​
Vice President of Clinical Affairs​
Jeffrey Starling​
Vice President of Sales​
Christopher Machuzak​
Vice President of Sales​
Stephanie Tipton​
Vice President of Marketing​
Benson Suen​
Vice President of International Sales​
Sean Delaney​
Vice President of Regulatory Affairs and Compliance​
David Solomon​
Vice President of Business Development​
Joseph C. Sardano​
Co-Founder, Chairman & CEO​
Michael Sardano​
President & General Counsel​
Javier Rampolla
Chief Financial Officer​
Maggie Martinez​
Chief Operational Officer
Emiliano Sosa​
Chief Technology Officer​
Monica DiGioia​
Vice President of Clinical Affairs​
Jeffrey Starling​
Vice President of Sales​
Christopher Machuzak​
Vice President of Sales​
Stephanie Tipton​
Vice President of Marketing​
Benson Suen​
Vice President of International Sales​
Sean Delaney​
Vice President of Regulatory Affairs and Compliance​
David Solomon​
Vice President of Business Development​
Kenrick A. Spence​
MD, FACS​
Robert E. Beer​
MD​
Michael H. Gold​
MD, FAAD​
David J. Goldberg​
MD, JD​
Dr. Kevin Schewe​
MD​
Brian Berman​
MD, Ph.D.​
William I. Roth​

MD

Angela M. Abbatecola​
MD, Ph.D​
Kenrick A. Spence​
MD, FACS​
Robert E. Beer​
MD​
Michael H. Gold​
MD, FAAD​
David J. Goldberg​
MD, JD​
Dr. Kevin Schewe​
MD​
Brian Berman​
MD, Ph.D.​
William I. Roth​

MD

Angela M. Abbatecola​
MD, Ph.D​
Joseph C. Sardano​
Co-Founder, Chairman & CEO​
John Heinrich​
PhD​
Anthony B. Petrelli​
Sam O'Rear​
Bill McCall​
Megan Cornish​
Joseph C. Sardano​
Co-Founder, Chairman & CEO​
John Heinrich​
PhD​
Anthony B. Petrelli​
Sam O'Rear​
Bill McCall​
Megan Cornish​

Our Mission

Our goal is to be recognized as the worldwide leader for non-invasive skin cancer treatment by offering safe and effective medical devices that are manufactured in the USA. Our Company is deeply committed to upholding the principles of Honesty and Integrity. These two guiding principles support our efforts to deliver the very best skin cancer treatment to patients every day. We will only introduce products that provide our Physicians with the ability to cure cancer while at the same time maintain a patient’s dignity and quality of life. We will accomplish all this while rewarding our customers and investors with a solid return.

Our Vision

We will be recognized as the worldwide leader in delivering non-invasive and pain free treatments for skin cancer. Our technologies will be embraced by patients and physicians alike so that SRT becomes the primary skin cancer treatment option. We will supply the market with safe and efficient technologies. Our company is customer-focused and responsive to change, balanced by a clear understanding that value and quality guide our decision making and that we always conduct business with Honesty and Integrity.

The Sensus Difference

At Sensus Healthcare, we are devoted to making a difference in the lives of people who suffer from non-melanoma skin cancer and unsightly keloid scarring.

By designing and manufacturing safe and reliable state-of-the-art Superficial Radiation Therapy technology right here in the United States, we are providing compassionate dermatologists and oncologists around the world with a non-surgical treatment option that empowers them to cure patients without compromising patient confidence, dignity or quality of life.

Patient & Doctor Advocates

Keloid Patient Testimonials
Non-Melanoma Skin Cancer Patient Testimonials
Non-Melanoma Skin Cancer Outcomes

Success Stories

Utilizing the SRT Keloid Treatment to Help Change Lives and Improve Non-Melanoma Skin Cancer Outcomes

Jeff Goldstein – Skin Cancer and SRT

Tony Perkins – Teacher from St. Louis

Frequently Asked Questions

What kind of conditions can be treated with the SRT-100™?

The SRT-100™ is an excellent treatment option for patients with the following conditions:

  • Keloid scars
  • Basal cell carcinoma
  • Squamous cell carcinoma
  • Metatypical carcinoma
  • Cutaneous appendage carcinoma
  • Actinic keratosis
  • Kaposi’s sarcoma
What is the cure rate of basal and squamous cell skin cancer when treated with the SRT-100™?

The SRT-100™ is comparable to surgery and is 97% effective in curing basal and squamous cell skin cancer.

What is the cure rate for keloids with the SRT-100™?

The SRT-100™ is very effective in treating keloids and boasts a cure rate of 90%.

How long is a typical treatment?

Depending on the treatment protocol your physician chooses for your particular case, you may need several treatments per week for up to several weeks.

Is the SRT-100™ a safe treatment option?

The SRT-100™ is a safe and proven technology that effectively treats non-melanoma skin cancers, keloid scarring, actinic keratosis and Kaposi’s sarcoma. It is utilized by dermatologists and radiation oncologists all over the world because it delivers good patient outcomes.

What should I expect from SRT-100™ treatment?

You should expect the same results as surgery, but with these additional benefits:

  • No pain
  • No anesthesia
  • No cutting
  • No bleeding
  • No stitching
  • No scarring
  • No interruption of lifestyle
Will I need reconstructive surgery post treatment?

No. The SRT-100™ is a non-invasive procedure. Since it does not require incisions, patients are not left with any scarring post-treatment.

Is the SRT-100™ cleared by the FDA?

Yes, the SRT-100™ has been cleared by the Federal Drug Administration for use on the entire body—making it especially effective in the treatment of non-melanoma skin cancer and keloid scars.

In cases where there are larger possible risks, you may be asked to agree in writing to the doctor’s plan for your care. This is part of informed consent. It recognizes your need to know about a procedure, surgery, or treatment, before you decide whether to have it. 

It’s common to go through the informed consent process before starting cancer treatment. If you are getting more than one type of treatment, you will likely need separate informed consents for surgery, chemotherapy, and radiation. 

After your first talk with your doctor, you may have only a general idea of the treatment plan. You’ll likely want to know more so that you can think about the ways this plan may affect your health and your life. In order to freely decide whether the risks are worth the benefits you expect to get from the treatment plan, you must understand the risks and drawbacks of the plan. Most people find that they need to get some questions answered before they can decide on a treatment plan that carries some risk for them. 

Informed consent is a process that includes all of these steps: 

You are told (or get information in some way) about the possible risks and benefits of the treatment. 

You are told about the risks and benefits of other options, including not getting treatment. 

You have the chance to ask questions and get them answered to your satisfaction. 

You have had time (if needed) to discuss the plan with family or advisors. 

You are able to use the information to make a decision that you think is in your own best interest. 

You share your decision with your doctor or treatment team. 

If you have gone through these steps and decide to agree to the treatment or procedure, you are usually asked to sign a paper called a consent form. The completed and signed consent form is a legal document that lets your doctor go ahead with the treatment plan. The consent form names the procedure or treatment to be done. The rest of the form may be very general, stating only that you have been told about the risks of the treatment and other available options. Or it may be very detailed, outlining what the risks and other options are. Depending on how it’s presented, you may sign for one certain procedure or treatment, or you may give blanket approval for any treatments and procedures that the health provider decides are needed. 

From the doctor’s viewpoint, informed consent means: 

A doctor or nurse must make every effort to be sure the patient understands the purpose, benefits, risks, and other options of the test or treatment. Then the doctor or nurse must get the patient’s consent before starting. In some cases, even a simple blood test or an injection (“shot”) requires written consent from the patient. 

As long as adult patients are mentally able to make their own decisions, medical care cannot begin unless they give informed consent. 

If the patient is a minor (under age), has a serious mental disability, or cannot give consent, then the parent, legal guardian, or a person authorized by the court must give consent before treatment can start. This is usually a close family member who has reason to know what the patient would want. (See “Who besides the patient can give consent?” in the section “What are the legal requirements of informed consent?”) As some very public court cases have shown, an elaborate legal system is in place to guide cases in which the patient is mentally or physically unable to give informed consent for treatment. These cases have come up when the patient is in a coma (unconscious) or on life support. 

Sometimes health care workers refer to the consent form itself as an “informed consent.” This is not quite accurate. Informed consent is the process and actions that take place as you learn about and think about a treatment before you agree to it. Your signature on the form is taken to be evidence that this took place. If you decide that you do not want the procedure or treatment, you should not sign the consent form. In this case, you may be asked to sign an informed refusal form or a form that states you are choosing not to follow medical advice. Your signature on this form implies that you know the risks of refusing, so be sure that you understand these risks and know your other options before you sign. 

What are the installation requirements for the SRT-100™?
The SRT-100™ is a compact, low-profile unit that has a space-saving 30” x 30” footprint. Medical-grade wheels and a standard wall socket plug-in make it easy to position the unit nearby so you can provide patients with safe, painless and effective treatment right in your office instead of referring them to another care provider.
What is the difference between the SRT-100™ and other radiation therapy machines?
Unlike more powerful radiation therapy devices, the SRT-100™ delivers a precise, calibrated low-dose. 100% of the dose is deposited at the surface, with a sharp falloff in dose, minimizing radiation exposure to underlying tissues. As a result, the SRT-100™ does not harm surrounding or underlying healthy tissue while targeting cancer cells or keloid scars. The SRT-100™ offers multiple energies to maximize the treatment results for various indications and lesions. Additionally, the SRT-100™ requires no consumables leading to substantial cost savings.
Are there any consumables I will need to buy and/or replace?
No, the SRT-100™ does not require consumables.
What areas of the body can be treated with the SRT-100™?
The SRT-100™ can be used to treat lesions on the arms, legs, back and trunk, but it is especially well suited for skin cancers of the head and neck regions—the fold in the nose, eyelids, lips, corners of the mouth, and the lining of the ear—areas that would otherwise lead to a less than desirable cosmetic outcome. SRT is also a great treatment option for patients who are considered high risk for surgical procedures.
Interested in Learning More About Our SRT Solutions?

Joseph C. Sardano

Co-Founder, Chairman & CEO

A recognized leader in the healthcare industry, Joe Sardano has spent more than 30 years in management and marketing. He has a successful history of introducing and commercializing new technologies and services in many areas, including electronic brachytherapy, PET and PET/CT, SPECT, MRI, lithotripsy and digital radiography. Before joining Sensus Healthcare, Sardano held leadership and management roles at CTI Molecular Imaging, GE Medical Systems, Siemens Medical Systems, Elscint Inc and Toshiba America Medical Systems, among others.

Michael Sardano

President & General Counsel

Michael Sardano has served in many capacities at Sensus Healthcare, Inc. since 2013. Michael works on a range of issues for Sensus, including, State and Federal Regulatory Matters, Government Affairs, and SEC Compliance. Prior to joining Sensus, Michael served on the United States Senate Rules & Administration Committee working on campaign finance reform and 501(c)(4) “SuperPAC” regulations during the 2012 Presidential Election. A licensed attorney in the State of Florida, Michael graduated from Bentley University in 2010 with a Bachelor of Science in Management & Finance and graduated from New England School of Law in 2013 receiving his Juris Doctor.

Javier Rampolla

Chief Financial Officer

Javier Rampolla has been director of accounting and reporting/controller at Sensus since 2015 and has more than 20 years of financial experience, holding positions of increasing responsibility at a number of public and private companies. He played an important role in managing the Sensus Healthcare’s initial public offering in June 2016 and worked to apply new U.S. GAAP guidelines for revenue recognition and leases. His experience includes three years as the assistant controller for Latin America at Stanley Black & Decker, where he centralized accounting functions for Central America and the Caribbean by achieving synergies that reduced cost and headcount by 20%. He was also responsible for implementing Sarbanes-Oxley financial controls. Mr. Rampolla has a B. A. in accounting from the University of Massachusetts in Boston.

Maggie Martinez

Chief Operational Officer

Maggie Martinez has been with Sensus Healthcare since 2013. Originally hired as a Customer Support Specialist, she provided real time technical support and led the team of field service engineers. She was promoted to Director of Field Operations in 2018, and most recently served as the Vice President of Operations. Maggie’s involvement in all post-sales activities, with an emphasis in customer satisfaction, technical support, and asset management with Sentinel Cloud™ has made her an integral part of the operations team. She holds a B.B.A. in Business Administration from Stetson University.

Emiliano Sosa

Chief Technology Officer

Mr. Sosa joined Sensus as Vice President of Technology Development with extensive experience in bank alarm systems, computer graphics, asset tracking, medical devices and artificial intelligence. In his 25+ years of experience, amongst his accomplishments are the introduction and engineering of the first GPS device in the Argentina market with real time streaming video cameras for vehicles and automated asset tracking systems (founding Overmax S.A. in 2007 ). His company in the U.S. was recognized as 2016 small business of the year. He has also designed and developed in the late 90’s electroencephalography and brain mapping devices, implementing the first 3-D EEG Brain Mapping medical devices and polysomnography machines at the time. In his new position he is charged with overseeing and expanding the company’s team of engineers to provide dependable and differentiated technologies to customers and their patients. A priority focus will be on expanding the capabilities and indications of the company’s Sentinel™ technology. Sentinel provides asset management and HIPAA-compliant patient data and storage capability, and also contains the software necessary to support shared service models including direct patient billing. Mr. Sosa studied software engineering at the National University of Technology in Buenos Aires, international marketing and foreign trade at the University of Buenos Aires in Argentina

Monica DiGioia

Vice President of Clinical Affairs

Monica is a highly Experienced Application Specialist with a demonstrated history of working in the medical device industry. DiGioia has worked with Sensus Healthcare for almost a decade and is an expert in Healthcare Information Technology (HIT), Electronic Medical Record (EMR), Sales, and Clinical/ Hospital Affairs. Graduated from Hailfax Medical Center School of Radiology.

Jeffrey Starling

Vice President of Sales

Jeffrey Starling was hired by Sensus as Southwest Account Executive in 2016 and was promoted to Southeast Regional Manager in 2020. He previously served as Director of Business Development at Fallene Cosmeceutical, Ltd. and in various sales and business development positions at Biopelle, Inc. He holds a B.A. in Marketing Communications from Southern Methodist University.

Christopher Machuzak

Vice President of Sales

Christopher Machuzak joined Sensus in 2012 as an Account Executive and was promoted to Sales Manager in 2017. He was previously a Territory Manager at Dermpath Diagnostics. Mr. Machuzak received a B.S. in Education from Mansfield University of Pennsylvania.

Stephanie Tipton

Vice President of Marketing

Ms. Tipton joined Sensus in June of 2021 as the Director of Digital Marketing, revamping the company’s social media and on-line outreach, which resulted in a dramatic increase in patient and physician inquiries. She has also worked closely with the company’s clinical, sales, and engineering teams to provide a more comprehensive approach to the product portfolio. As an experienced sales & marketing professional with a record of success, she was President of Tipton Group, a marketing consulting firm prior to joining Sensus. Previously she was for six years Industrial Director/Director of Sales for Nova Medical Centers in Knoxville, Tenn. Ms. Tipton holds a B.S. degree in biology and minor in business administration from the University of Tennessee, Knoxville.

Benson Suen

Vice President of International Sales

Mr. Suen brings to Sensus nearly 20 years of business development, sales and regulatory experience supporting the distribution of U.S. medical devices and other products throughout Asia and in particular China.  

Most recently, he was Director, Business Development at Fosun Pharma, with responsibility for identifying complementary products to expand the Fosun/Chindex product portfolio and providing strategies for companies to enter the China market.  

From 2010 to 2016 he was Senior Manager, Business Development and Regulatory at Chindex International, prior to its acquisition by Fosun Pharma.  At Chindex, Mr. Suen was part of a team that initiated and managed the first robotic surgery reference center in China, and established one of the most successful da Vinci Surgical System marketing programs in the world. 

From 2004 to 2010 he served as Manager, Business Development at Prosperity Link in Beijing, where he was responsible for the annual sourcing of more than $50 million in food products from the U.S.

Sean Delaney

Vice President of Regulatory Affairs and Compliance

Sean brings to Sensus nearly 20 years of product development experience in regulatory affairs, quality assurance and regulatory compliance, including worldwide regulatory clearances and approvals, development and product quality, international standard compliance and post–market surveillance. Much of his experience is in software-controlled image-guided radiation therapy systems. Most recently, Mr. Delaney worked at ViewRay, with responsibility for regulatory affairs and compliance, quality assurance, radiation safety and U.S. Food and Drug Administration submissions. He holds a B.S. in physics from San Jose State University and an MBA from Santa Clara University, Leavey School of Business.

David Solomon

Dr. Solomon joined Sensus Healthcare in 2019 as Vice President, Business Development. Over his four years with Sensus, David has taken on additional responsibilities related to clinical development, clinical affairs, regulatory, investor relations and sales. Prior to Sensus, Dr. Solomon worked at Roth Capital Partners as a Medical Device equity research analyst, covering microcap and small cap companies. David graduated from Tufts University School of Medicine in 2013 and from the University of Pennsylvania School of Engineering and Applied Science in 2008 with a B.S.E. in Bioengineering.

Kenrick A. Spence

MD, FACS

Kenrick Anthony Spence, M.D., F.A.C.S., Medical Director and Chief Plastic Surgeon at the Hillcrest Plastic Surgery since 1999, specializes in Advanced Facial Rejuvenation, Facial Surgery and Facial Revision Surgeries, Body Contouring and Body Contouring Revisionary Surgeries. Throughout his tenure at Hillcrest Plastic Surgery, Dr. Spence has led a team comprised of Dermatologists, Plastic Surgeon, Anesthesiologist, Nurse Practitioners, Aestheticians, Registered Nurses, Medical Assistants, Surgical Technicians, Patient Care Coordinators and Administrators.

Born in London, England, of Jamaican parentage, an alumnus of Calabar High School and the University of the West Indies, Dr. Spence has been in the practice of medicine since 1990. In 1999, Dr. Spence established his private practice in Plastic and Reconstructive Surgery in Orlando, Florida. Dr. Spence’s quest to combine the artistry of plastic surgery with the aesthetic needs of each patient began while pursuing his medical career at the University Of Connecticut School Of Medicine, 1986. In 1991, at the invitation of The Saint Raphael’s Hospital, Yale University, Dr. Spence completed a five year program in general surgery achieving Board Certification in General Surgery. From there, he journeyed to his plastic surgery fellowship at the University of Texas at Galveston achieving his Board Certification in Plastic and Reconstructive Surgery.

In 2005, Dr. Spence situated his practice in the state-of-the-art facility at 130 Hillcrest Street, located on the out skirts of Downtown Orlando, conveniently located near main traffic arteries in Central Florida and close proximity to one of the country’s largest international airports. This location boasts a 6,002 square feet facility consisting of multi-facetted examination rooms, an advanced skincare center, a keloid center and a surgery center. The latter is certified by the credentialing body, American Association for Accreditation of Ambulatory Surgery Facilities, Inc. (AAAASF) since 2006. This onsite surgery center affords patients the convenience, privacy and safety for surgical procedures performed under general and local anesthesia.

Dr. Spence considers the changes in the lives of many to be the hallmark of his career. He is certified by the American Board of Plastic Surgery, a member of the American Society for Aesthetic Plastic Surgery and a Fellow of the American College of Surgeons. As a father and husband Dr. Spence brings to his practice of medicine an appreciation of life.

Voted Orlando’s best Plastic Surgeon 6 years in a row, and recognized by one of the world’s largest pharmaceutical companies as a Master Injector, Dr. Spence is a pioneer and internationally recognized as an expert in his field. Some patients refer to him as a “magician”. He has helped thousands of patients reclaim their youthful appearance and boost self-esteem.

Dr. Spence is a humanitarian at heart, proudly an active donor to Habitat for Humanity, he has provided pro-bono services for women who are victims of domestic violence and last but not least his selfless contribution of time and work associated with the Austin Smiles in El Salvador.

Dr. Spence has earned an enviable reputation with “Sculptease”, a procedure designed, developed & trademarked by him. Also developed by Dr. Spence is A.S.C.R “Aesthetic Skin Cancer Reconstruction” which is the integration and exciting blend of cosmetic and reconstructive surgery.

Robert E. Beer

MD

Director of Balfour Dermatology, Dr. Beer; dermatologist and MOHS surgeon, is passionate about the treatment and detection of skin cancer. Dr. Beer was the first in California to adopt SRT, a non-surgical treatment for skin cancer. He completed medical school at Baylor in Houston, Texas and his dermatology training at Columbia University in New York City. He completed his MOHS and Laser Fellowship in Kansas City, Missouri, additional training in Palm Springs, California. For his leading role in dermatology, Dr. Beer was elected to serve as Chairman of Dermatology for John Muir Hospital in Walnut Creek. Dr. Beer is a Fellow of American College of MOHS Micrographic Surgery and Cutaneous Oncology. Dr. Beer is board certified by the American board of Dermatology.

Michael H. Gold

MD, FAAD

Dr. Michael H. Gold is the founder of Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser & Rejuvenation Center, and Tennessee Clinical Research Center located in Nashville, Tennessee. Dr. Gold is also Clinical Assistant Professor at Vanderbilt University School of Nursing and Adjunct Assistant Professor at Meharry Medical College, School of Medicine also in Nashville, Tennessee. He is also a Physician Assistant Student Preceptor of Wake Forest School of Medicine in Winston Salem, NC. He is a Visiting Professor of Dermatology for Huashan Hospital, Fudan University in Shanghai, China (11/2006), Guangdong Provincial People’s Hospital, Guangzhou, China, as well as Visiting Professor of Dermatology at Number One Hospital of China Medical University (11/2008) in Shenyang, China. Visiting Professor Rongjun Hospital, Jiaxing, China, 2016. Additionally, he is Visiting Professor of Plastic Surgery, First People’s Hospital of Foshan, Guangzhou, China and The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang. In addition, he is Visiting Professor of Plastic Surgery, The People’s Hospital of Hunan Province.

Dr. Gold is a board-certified dermatologist and cosmetic surgeon who oversees the various facets of the Gold Skin Care Center’s operations: a combination of medical and surgical dermatology, cosmetic dermatology, aesthetic services, and research endeavors. Dr. Gold has earned a national and international reputation for providing patients with leading-edge technological advances and has expertise in all facets of dermatology and aesthetic care. The Tennessee Clinical Research Center is one of the leading dermatologic research institutions in the U.S. Dr. Gold is the author of over 300 published scientific articles, and 35 textbook chapters. He is the editor of two textbooks on photodynamic therapy and global use of PDT. Dr. Gold works as an associate editor with the majority of dermatology journals and actively contributes to the medical literature with his colleagues from around the world. In 2016, he became the Editor-in-Chief of the Journal of Cosmetic Dermatology. Dr. Gold speaks on national and international fronts, focusing on dermatology issues related to the use of lasers and energy-based devices, as well as the use of fillers and toxins in aesthetic and cosmetic dermatology. He has spoken on Practice Management issues in dermatology for almost 30 years. He lectures in venues around the world and is a sought-after contributor to educational meetings globally.

Dr. Gold is an active member of many of the leading dermatology and laser specialty societies in the U.S. and around the world. He is the founder and past President of the Dermatologic & Aesthetic Surgery International League (DASIL), whose mission is to teach dermatology and dermatologic surgery all over the world in a non-profit setting. This society has become one of the fastest-growing international dermatologic societies because of its core beliefs of teaching and transparency. Dr. Gold oversees the DASIL meeting, which attracts 150 faculty members, and upwards of serval thousand attendees from more than 40 countries. DASIL is primed to be the international dermatologic surgery society. He is a founding member and current President of the 5-Continent-Congress, one of the leading global aesthetic congresses. These meetings held in Barcelona, attract over 150 faculty and up to 1200 attendees. It has become one of the leading aesthetic meetings in the world. In addition, Dr. Gold is the President of the Symposium for Cosmetic Advances & Laser Education (SCALE), which is part of the Tennessee Society for Laser Medicine and Surgery. The meeting, which began 12 years ago, as an effort to educate and teach the proper use of lasers and injectables in the community. Since its onset, SCALE has grown in stature and regarded as one of the most influential aesthetic and dermatology meetings in the U.S. SCALE’s base is in Nashville, Tennessee and attracts an incredible faculty year after year.

David J. Goldberg

MD, JD

David J. Goldberg, MD, JD is recognized nationally and internationally for his innovative work with skin lasers, cosmetic dermatology and non-invasive facial and body rejuvenation techniques. A board-certified dermatologist who has been in practice since 1985, he has treated patients and taught doctors throughout the world in the use of these cutting-edge technologies.

Under his direction, Skin Laser & Surgery Specialists of New York and New Jersey has been a pioneer in making skin laser and cosmetic dermatology technologies available to the public. Dr. Goldberg earned his medical degree from Yale University. He completed his dermatology residency and dermatologic surgical fellowship at New York University Medical Center. He is a clinical professor and former director of Mohs Surgery and Laser Research in the department of Dermatology at NY’s Icahn School of Medicine at Mount Sinai.

Dr. Goldberg has published over 160 academic papers and has contributed to over 15 academic textbooks. He has authored textbooks on laser dermatology, laser hair removal, laser facial rejuvenation, photodamaged skin, skin wrinkle fillers, acne, rosacea, unwanted fat and cellulite . He has also co-authored two books for the general public: Light Years Younger and Secrets of Great Skin. Dr. Goldberg is active in professional societies and was elected president of the American Society for Lasers in Medicine & Surgery. He has also served as chairperson of the Ethics Committees of the American Academy of Dermatology, the American Society for Lasers in Medicine and Surgery and the American Society for Dermatologic Surgery. He has sat on the board of directors of the American Academy of Dermatology, the American Society for Lasers in Medicine and Surgery, the American Society for Dermatologic Surgery and the International Society for Dermatologic Surgery. He has also served as a co-vice-president of the Skin Cancer Foundation. Dr. Goldberg was the first recipient of the prestigious Leon Goldman award, named after the founder of laser surgery.

Additionally, Dr. Goldberg was named one of the “Top Ten Laser Surgeons in the U.S.” by Self magazine, one of the “Best Doctors in America” by Woodward/White, Inc., a “Best Doctor in America” by Best Doctors Inc. and one of the “Best Dermatologists in New Jersey” by New Jersey Monthly. Dr. Goldberg has always been eager to advance the skill levels of his colleagues. He has an active fellowship Program at his practice that draws the “best of the best” dermatologists and Physician Assistants, many of whom join Skin Laser & Surgery Specialists of New York and NY and NJ after their fellowship is complete. Lastly, his legal background and expertise in Health Care Law (he has taught Health Care Law at NY’s Fordham Law School for over 15 years) puts Dr. Goldberg at the forefront in understanding the economic, legal and ethical issues of today’s health care and dermatology delivery systems.

Dr. Kevin Schewe

MD,

Dr. Kevin Schewe is a Board-Certified Radiation Oncologist and a Fellow of the American College of Radiation Oncology. Dr. Schewe has devoted his 30-year medical career and practice in the fight against cancer. He currently serves as Medical Director of Radiation Oncology at the Red Rocks Medical Center in Golden, Colorado (https://radiationoncologyatredrocks.com/). The Red Rocks Radiation Oncology Center was created by Dr. Schewe and is beautifully and warmly designed to feel more like a comfortable home for cancer patients rather than a traditional medical facility.

Dr. Schewe serves as Chairman of National Cancer Survivors Day at the Red Rocks Center the first Sunday of every June and that event has become a highly-anticipated and joyful tradition in Jefferson County. He has been named to “5280 Top Docs” multiple years and is known as a strong advocate of the personalized treatment approach for each cancer patient entrusted to his care.

Dr. Schewe has also developed a premium line of skin care and cosmetic products that help to naturally heal, protect, repair and subsequently maintain not only the damaged skin of cancer patients, but also individuals who have experienced skin damage resulting from aging, dryness, UV exposure, other illnesses, and environmental pollution. These products are manufactured and sold by Dr. Schewe’s company Elite Therapeutics (https://www.elitetherapeutics.com/). Dr. Schewe also serves as Chairman of the Board of a publically-traded, microcap, renewable green-energy company called VIASPACE (https://viaspace.com/) which has a proprietary product called Giant King Grass that is a high-yielding biomass source that creates carbon-neutral bioenergy and biofuels.

Brian Berman

MD,

Professor Emeritus of Dermatology University of Miami Miller School; Co-Director Center for Clinical and Cosmetic Research Skin and Cancer Associates, Aventura, FL Dr. Brian Berman is Professor Emeritus of Dermatology and Dermatologic Surgery at The University of Miami Miller School of Medicine and has had the honor of serving as a member of the Board of Directors and is presently Vice President-Elect of the American Academy of Dermatology and the American Academy of Dermatology Association and Vice President of the American Dermatological Association. He has served as Professor of Dermatology and Internal Medicine at the University of Miami, Medical Director for Dermatology for inpatient and outpatients at Dade County’s Jackson Memorial Hospital, Professor of Dermatology and Vice-Chairman of the Department of Dermatology at The University of California, Davis, Chief of the Dermatology Service at the VA Medical Center, Martinez, CA, and Chairman of the Department of Dermatology at The Mount Sinai Medical Center in Miami Beach, Florida. He is past President and Founder of The National Association of Veterans Affairs Dermatologists, Chaired the Dermatology Field Advisory Group for The Department of Veterans Affairs, is a member of the nominating committee of the American Dermatological Association, Treasurer of the American Cutaneous Oncology Society, and serves on the Scientific Advisory / Editorial Boards of The European Journal of Dermatology, Journal of Cosmetic Dermatology, and SKINmed, Journal of Clinical and Aesthetic Dermatology, edited The Miami Review series and was a member of the Board of Trustees of the Sulzberger Institute for Dermatologic Education.

In addition to caring for patients at Skin and Cancer Associates in Aventura, FL, Dr. Berman also attends and teaches at the Miami Veterans Affairs Medical Center. As Co-Director of the Center for Clinical and Cosmetic Research he continues his broad-based clinical research program while focusing laboratory investigations on the study of the control of scarring. He has presented at over 300 local,regional, state, national and international Dermatologic Societies and meetings. He is the author of more than 250 peer-reviewed scientific and clinical articles, chapters and books, is the recipient of the Dean’s Senior Faculty Clinical Research Award from the University of Miami School of Medicine, was bestowed the “Scientist of the Year” Award from Sigma Xi the Science and Research Honor Society and is included in U.S. News and World Report’s “Best Doctors in America”.

William I. Roth

MD,

William I. Roth, MD, is a board-certified dermatologist who has been in practice for 34 years. His conviction in the superiority of superficial radiation therapy (SRT) for skin cancer treatment dates back to his joint practice with Victor H. Witten, MD—and Witten’s work with his past partner, Marion Sultzberger, MD. Dr. Roth continues the legacy and breakthrough science of their innovations. Dr. Witten and Dr. Roth worked together demonstrating SRT excellent results for almost 15 years in Miami. The availability of new, safer and improved SRT delivery systems from Sensus Healthcare now helps Dr. Roth provide SRT in his private practice in Boynton Beach, Florida. Dr. Roth is a clinical professor in The University of Miami School of Medicine Department of Dermatology, a Fellow of the American Academy of Dermatology and a member of the American Medical Association. Among his many past positions, he has served as President of the Florida Society of Dermatology and Dermatological Surgery and President of the Dade County Medical Association. Dr. Roth also served on the Board of Trustees of The Public Health Trust of Metropolitan Dade County (Jackson Memorial Hospital) from 1992 to 1993. He is pleased to serve on the Advisory Board of Sensus Healthcare.

Angela M. Abbatecola

MD, Ph.D.,

Angela M. Abbatecola, MD, Ph.D., has served as a contract researcher in the Scientific Direction at the Italian National Research Center on Aging (INRCA) in Ancona, Italy since 2009. She studied chemistry and obtained her Bachelor of Science from Syracuse University in Syracuse, New York in 1994 (summa cum laude). She then went on to earn her medical degree in 2001, followed by her Ph.D. in 2009 at the Second University of Naples in Naples, Italy—achieving the highest honor of recognition (summa cum laude) for both. Dr. Abbatecola is currently a member of two Italian committees in Rome focused on study protocols for older people in Italy—Geriatric Working Group at the Agenzia Italiana del Farmaco (AIFA) and the Scientific Board of the Società Italiana Geriatri Ospedalieri (SIGOS). Dr. Abbatecola has authored more than 35 original papers, reviews, editorials, and chapters in diverse medical books. Her published work addresses many issues regarding the aging process and the difficulties often encountered when treating elderly patients. She continues to investigate ways to identify biomarkers for frailty syndrome, cognitive decline and sarcopenia.

John Heinrich

PhD

John Heinrich has been involved in the development and management of a wide range of diagnostic imaging, therapeutic, medical diagnostic and scientific instrument companies for more than 25 years. He played a key role in the development of mobile MRI systems in the early 1980s and served as Vice President of MRI products at Technicare Corporation. Over the past 15 years, his responsibilities have included serving as: President and Chief Operating Officer of Technomed International USA Inc., a leading developer and marketer of therapeutic technology; President and Chief Operating Officer of Summit World Trade, a diversified group of health care and technology companies; President and Chief Executive Officer of Otsuka Electronics USA Inc., a developer and marketer of medical and scientific equipment; and President and Chief Operating Officer of Meretek Diagnostics Inc., a developer and marketer of medical diagnostics. Dr. Heinrich was responsible for the sales of Otsuka’s medical and scientific equipment businesses to Elscint Ltd. and Varian Instruments, respectively, along with the acquisition of Cambridge Isotope Laboratories and Meretek Diagnostics. He is also a cofounder and director of Acuitas Medical, a developer of unique MRI software, and managing partner of Revolution NMR, LLC and Kansas Analytical Services, LLC.

Anthony B. Petrelli

Mr. Petrelli received his BS in Business (Finance) and his Masters of Business Administration (MBA) from the University of Colorado and a Masters of Arts in Counseling from Denver Seminary. He began his career in 1972 and since that time has managed the Corporate Finance departments for Bosworth, Sullivan & Co., Hanifen,Imhoff, Inc. and his current position at NTB Financial Corporation. Mr. Petrelli has served on numerous regulatory and industry committees including service on the FINRA Corporate Finance Committee, the NASD Small Firm Advisory Board, the FINRA Fixed Income Committee, the FINRA District Surveillance Committee, District 3 and as the Chairman of the FINRA District Business Conduct Committee, District 3, FINRA Statutory Disqualification Board and as a FINRA Arbitrator and as a member of the Task Force on Future of Shared State and Federal Securities Regulation, North American Securities Administrators Association, Inc. (NASAA) among others. Mr. Petrelli has also served as the Chairman of the Regional Investment Bankers Association. Mr. Petrelli has been involved in many aspects of the securities industry. He has had extensive experience in his 40 years in the areas of operations, sales, trading, management of sales, underwriting and corporate finance.

Sam O'Rear

Sam O’Rear has 40 years of experience in the healthcare industry as a clinician, a sales and marketing director, vice president, general manager, owner and principal in several healthcare services businesses. His experience as clinician in the ancillary hospital services was garnered primarily in the UAB Health System (1970-74). From 1974 to1990, he held sales and marketing positions in Siemens and GE Healthcare. O’Rear rose from management posts in sales, financing, asset management and marketing to vice president and general manager of X-Ray Business. O’Rear left GE to become the chief operating officer for Medical Imaging Centers of America in 1990. That year, he also founded The Innovation Group, Inc. (TIGI). Over the years, he has acquired several consulting firms to expand TIGI into a multi-partner healthcare consultancy. Today, TIGI provides commercialization services to a client base extending from start-ups to Fortune 500 companies represented by GE, Philips, Toshiba, Xerox, Roche, HCA, VHA, MedAssets, Compass Group, Cobalt, Sysmex, Cobalt, etc. O’Rear holds a Bachelor of Science in Chemical Engineering and a Master’s in Psychology. He is the senior partner of Total Innovation Group, Inc., and is an investor, principal and board member in several start-ups in the healthcare industry (Data Advantage, Remcare, Sensus, UP Labs).

Bill McCall

Bill McCall has served as a financial advisor and portfolio manager for over 43 years and is currently a Managing Director of Heritage Advisory Group, a financial advisory practice of Ameriprise Financial Services Inc. Other business activities include Managing Partner of Investors Capital Alliance LLC, a consulting company; CEO of WMW Partners LLC, a holding company; member of Pandora Mineral Resources LLC and Board member of Cherokee Farm Partners Inc., an entity of the University of Tennessee Research Foundation. Bill holds a Bachelor of Science Degree in Business Administration with a concentration in Finance and Marketing from the University of Tennessee and he received a Chartered Wealth Advisor designation from Michigan State University.

Megan Cornish

Ms. Cornish brings to Sensus more than a decade of experience working on Capitol Hill in several Congressional offices and as a lobbyist advising a broad range of companies in a variety of industries. Since 2016 she has served as vice president of external affairs and corporate secretary for FoodMaven Corporation, a Colorado Springs-based company that sells unsold and oversupplied food from distributors, manufacturers and producers to restaurants and institutional buyers. Since 2013 she has been an independent consultant to corporations, law firms, not-for-profit organizations and political campaigns on government relations and lobbying.

Ms. Cornish served from 2012 to 2013 as Legislative Assistant to Rep. Tim Holden of Pennsylvania, who was a member of the U.S. Committee on Agriculture from 1992 to 2014. From 2009 to 2012 while serving as Legislative Assistant to Rep. Edolphus Towns of New York, she researched and analyzed immigration, science and technology, homeland security, animal rights issues and special projects while he served as Chairman of the U.S. House Committee on Oversight and Government Reform. Earlier in her career she contributed to multiple political campaigns for candidates running for local, state and federal offices.